Company intelligence / Profile preview
AngioLab, Inc.
Daejeon, Daejeon, South Koreaangiolab.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AngioLab specializes in developing therapeutics based on angiogenesis inhibitors. The company has advanced several candidates into clinical trials targeting conditions such as AMD, MASH/NASH, periodontitis, otitis media with effusion, psoriasis, rosacea, and abdominal obesity. As of early/mid–2024:
- AL101–AMD received IND approval to begin a Phase III trial for wet age-related macular degeneration.
- AL101–OME completed a Phase IIa trial for otitis media with effusion.
- AL101–MASH completed a Phase IIa trial targeting metabolic syndrome-related fatty liver disease.
- AL102-PDT completed a Phase II trial for periodontal disease.[2]
The company also markets Ob-X—a functional food ingredient clinically shown to reduce visceral fat—and has developed antibody-drug conjugates through academic collaborations.[2]
- Therapeutic areas
- Metabolic DisordersOphthalmologyDermatologyOncologyInfectious Diseases
- Modalities
- Small molecules (angiogenesis inhibitors)Antibodies (e.g., AL201-AB)Functional foods (Ob-X for visceral fat reduction)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Hallym Pharmaceutical/Sangmyung Innovation – technology transfer of AL101-AMDXL-protein – MOU regarding PASylation technology
Beyond the preview
Go deeper on AngioLab, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AngioLab, Inc..